175 related articles for article (PubMed ID: 26511811)
1. Aberrant Epigenetic Modifications of LPHN2 Function as a Potential Cisplatin-Specific Biomarker for Human Gastrointestinal Cancer.
Jeon MS; Song SH; Yun J; Kang JY; Kim HP; Han SW; Kim TY
Cancer Res Treat; 2016 Apr; 48(2):676-86. PubMed ID: 26511811
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of FAT4 contributes to gastric field cancerization.
Yoshida S; Yamashita S; Niwa T; Mori A; Ito S; Ichinose M; Ushijima T
Gastric Cancer; 2017 Jan; 20(1):136-145. PubMed ID: 26792292
[TBL] [Abstract][Full Text] [Related]
3. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of ADAMTS18 by aberrant promoter hypermethylation contribute to lung cancer progression.
Zhang Y; Xu H; Mu J; Guo S; Ye L; Li D; Peng W; He X; Xiang T
J Cell Physiol; 2019 May; 234(5):6965-6975. PubMed ID: 30417422
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
6. Epigenomic biomarkers for prognostication and diagnosis of gastrointestinal cancers.
Wong CC; Li W; Chan B; Yu J
Semin Cancer Biol; 2019 Apr; 55():90-105. PubMed ID: 29665409
[TBL] [Abstract][Full Text] [Related]
7. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
[TBL] [Abstract][Full Text] [Related]
8. Alteration in DNA methylation patterns: Epigenetic signatures in gastrointestinal cancers.
Heydari Z; Moeinvaziri F; Mirazimi SMA; Dashti F; Smirnova O; Shpichka A; Mirzaei H; Timashev P; Vosough M
Eur J Pharmacol; 2024 Jun; 973():176563. PubMed ID: 38593929
[TBL] [Abstract][Full Text] [Related]
9. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
10. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
11. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
13. [Epigenetic Alterations in Gastrointestinal Cancers: Diagnostic and Therapeutic Applications].
Ushijima T; Maeda M; Kawachi A
Gan To Kagaku Ryoho; 2018 Jan; 45(1):1-7. PubMed ID: 29362296
[TBL] [Abstract][Full Text] [Related]
14. Site-Specific Hypermethylation of SST 1stExon as a Biomarker for Predicting the Risk of Gastrointestinal Tract Cancers.
Dai X; Sun X; Wu Y; Lv Z; Yu Z; Yuan Y; Sun L
Dis Markers; 2022; 2022():4570290. PubMed ID: 35242243
[TBL] [Abstract][Full Text] [Related]
15. Identification of long-range epigenetic silencing on chromosome 15q25 and its clinical implication in gastric cancer.
Kang JY; Song SH; Yun J; Jeon MS; Cha Y; Lee SH; Kim HP; Jeong EG; Han SW; Cho NY; Kook MC; Kang GH; Kim TY
Am J Pathol; 2015 Mar; 185(3):666-78. PubMed ID: 25576785
[TBL] [Abstract][Full Text] [Related]
16. Methylomic analysis identifies C11orf87 as a novel epigenetic biomarker for GI cancers.
Tran MTMT; Yeh KT; Chuang YM; Hsu PY; Low JT; Kumari H; Lee YT; Chen YC; Huang WH; Jin H; Lin SH; Chan MWY
PLoS One; 2021; 16(4):e0250499. PubMed ID: 33886682
[TBL] [Abstract][Full Text] [Related]
17. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer.
Kawamura YI; Toyota M; Kawashima R; Hagiwara T; Suzuki H; Imai K; Shinomura Y; Tokino T; Kannagi R; Dohi T
Gastroenterology; 2008 Jul; 135(1):142-151.e3. PubMed ID: 18485915
[TBL] [Abstract][Full Text] [Related]
18. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of the LINE-1 methylation levels in patients with gastrointestinal cancer.
Baba Y; Murata A; Watanabe M; Baba H
Surg Today; 2014 Oct; 44(10):1807-16. PubMed ID: 24150097
[TBL] [Abstract][Full Text] [Related]
20. Early Epigenetic Markers for Precision Medicine.
Dumitrescu RG
Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
